An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy (Q39110166)

9 September 2017

An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy (English)

1 reference

9 September 2017

1 reference

1 reference

7

1 reference

9 September 2017

Vijay U Rao

1

1 reference

9 September 2017

Andrey Pavlov

2

1 reference

9 September 2017

Micki Klearman

3

1 reference

9 September 2017

David Musselman

4

1 reference

9 September 2017

Jon T Giles

5

1 reference

9 September 2017

Joan M Bathon

6

1 reference

9 September 2017

Janet S Lee

8

1 reference

9 September 2017

1 February 2015

1 reference

9 September 2017

Arthritis & Rheumatology

1 reference

9 September 2017

67

1 reference

9 September 2017

372-380

1 reference

9 September 2017

2

1 reference

Patterns of cardiovascular risk in rheumatoid arthritis

9 September 2017

1 reference

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

21 January 2018

1 reference

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

21 January 2018

1 reference

Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

21 January 2018

1 reference

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

21 January 2018

1 reference

Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis

21 January 2018

1 reference

The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis

21 January 2018

1 reference

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study

21 January 2018

1 reference

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

21 January 2018

1 reference

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

21 January 2018

1 reference

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

21 January 2018

1 reference

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

21 January 2018

1 reference

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure

21 January 2018

1 reference

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

21 January 2018

1 reference

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study

21 January 2018

1 reference

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

Integrated safety in tocilizumab clinical trials

21 January 2018

1 reference

Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritis

21 January 2018

1 reference

Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements.

21 January 2018

1 reference

Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor.

21 January 2018

1 reference

Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?

21 January 2018

1 reference

Relaxing the rule of ten events per variable in logistic and Cox regression

21 January 2018

1 reference

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.38920

1 reference

9 September 2017

1 reference